Health Canada, which has been accused of not providing the public with enough info about quality concerns over the drugs sold there, says it will increase the number of plant inspections it will do and put more information online, the Toronto Star reports. "Transparency initiatives related to inspections are a key priority to Health Canada," the regulator said in a a letter last month to drug manufacturers about its plans. The agency has been criticized for not letting the public know about problems with Canada-based Apotex, which has been repeatedly cited by the FDA for manufacturing problems at its plants in Canada and India. Story | More